logo
Plus   Neg
Share
Email

Janssen: Long-term Trial Shows TREMFYA As Efficacious Therapy In Plaque Psoriasis

Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) announced Monday new long-term plaque psoriasis data for TREMFYA (guselkumab).

The company noted that the first-in-class treatment showed consistent, high levels of skin clearance through four years in adult patients with moderate to severe plaque psoriasis.

In the open-label extension of VOYAGE 2, at four years, 80 percent of patients who were treated with guselkumab 100 mg every 8 weeks, achieved at least 90 percent improvement in the Psoriasis Area and Severity Index or PASI 90 score.

According to the company, Guselkumab is the first monoclonal antibody that selectively binds to the p19 subunit of IL-23, and inhibits its interaction with the IL-23 receptor, to have been approved by the European Commission.

Kristian Reichi, lead investigator of the VOYAGE 2 study, said, "Results from the VOYAGE 2 study demonstrate guselkumab as an efficacious therapy through four years, providing patients who may be experiencing chronic psoriatic symptoms with a long-term treatment option."

Separately, data from the randomised, placebo-controlled, head-to-head, Phase 3 VOYAGE 1 trial comparing patient-reported outcomes between those being treated with guselkumab and those being treated with adalimumab are also being shared online as a poster.

The new analysis show a higher proportion of patients treated with guselkumab reported symptom-free and sign-free status through 48 weeks versus adalimumab.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year. Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow.
Follow RTT